Cargando…

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC

SIMPLE SUMMARY: Targeted therapy has revolutionized the treatment of non-small cell lung cancer (NSCLC) and MET inhibition is a promising therapy for MET-dysregulated NSCLC. However, due to the lack of effective biomarkers, the clinical efficacy is unsatisfactory. This study aims to investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jie, Guang-Ling, Peng, Lun-Xi, Zheng, Mei-Mei, Sun, Hao, Wang, Song-Rong, Liu, Si-Yang Maggie, Yin, Kai, Chen, Zhi-Hong, Tian, Hong-Xia, Yang, Jin-Ji, Zhang, Xu-Chao, Tu, Hai-Yan, Zhou, Qing, Wong, Catherine C. L., Wu, Yi-Long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818927/ https://www.ncbi.nlm.nih.gov/pubmed/36612298 http://dx.doi.org/10.3390/cancers15010302

Ejemplares similares

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
por: Peng, Lun-Xi, et al.
Publicado: (2021)

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification
por: Sun, Dantong, et al.
Publicado: (2022)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Yoshimura, Katsuhiro, et al.
Publicado: (2021)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
por: Liu, Li, et al.
Publicado: (2021)

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
por: Presutti, Dario, et al.
Publicado: (2015)

Canadian Consensus Recommendations on the Management of MET-Altered NSCLC
por: Cheema, Parneet K., et al.
Publicado: (2021)

Overcoming MET-mediated resistance in oncogene-driven NSCLC
por: Reischmann, Nadine, et al.
Publicado: (2023)

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC
por: Kim, Nam Ah, et al.
Publicado: (2020)

Real-world insights into patients with advanced NSCLC and MET alterations
por: Bittoni, Marisa, et al.
Publicado: (2021)

Devil in the detail: MET overexpression fails as surrogate marker for MET exon 14 splice site mutations in NSCLC
por: Strickland, Matthew R., et al.
Publicado: (2020)

Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC
por: Jørgensen, Jan Trøst, et al.
Publicado: (2022)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
por: Wang, Kaiwen, et al.
Publicado: (2023)

Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
por: Cai, Boning, et al.
Publicado: (2021)

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study
por: Seto, Takashi, et al.
Publicado: (2021)

Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma
por: Wu, Ju-gang, et al.
Publicado: (2014)

Clinical and pathological characteristics of 11 NSCLC patients with c-MET exon 14 skipping
por: Chen, Hualin, et al.
Publicado: (2022)

Characterizing the roles of Met31 and Met32 in coordinating Met4-activated transcription in the absence of Met30
por: Carrillo, Emilio, et al.
Publicado: (2012)

Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment
por: Demuth, Christina, et al.
Publicado: (2017)

Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations
por: Paik, Paul K., et al.
Publicado: (2022)

Foretinib Enhances the Radiosensitivity in Esophageal Squamous Cell Carcinoma by Inhibiting Phosphorylation of c-Met
por: Chen, Guang-Zong, et al.
Publicado: (2017)

Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification
por: Ding, Caixia, et al.
Publicado: (2023)

Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting
por: Ai, Xinghao, et al.
Publicado: (2022)

MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC
por: Tyler, Logan C., et al.
Publicado: (2022)

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
por: Veillon, Remi, et al.
Publicado: (2022)

Targeting MET in cancer therapy
por: Mo, Hong-Nan, et al.
Publicado: (2017)

Longitudinal DNA methylation changes at MET may alter HGF/c-MET signalling in adolescents at risk for depression
por: Ciuculete, Diana M., et al.
Publicado: (2019)

Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies
por: Lau, Sally C.M., et al.
Publicado: (2023)

Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
por: Kou, Jianqun, et al.
Publicado: (2018)

Critical Role of MetR/MetB/MetC/MetX in Cysteine and Methionine Metabolism, Fungal Development, and Virulence of Alternaria alternata
por: Gai, Yunpeng, et al.
Publicado: (2021)

The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer
por: Liao, Haiyan, et al.
Publicado: (2021)

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
por: Tanaka, Hisashi, et al.
Publicado: (2021)

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC
por: Peters, T. L., et al.
Publicado: (2021)

The Role of MET in Resistance to EGFR Inhibition in NSCLC: A Review of Mechanisms and Treatment Implications
por: Feldt, Susan L., et al.
Publicado: (2023)

Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2021)

BDNF Val66Met Variant and Smoking in a Chinese Population
por: Zhang, Xiang Yang, et al.
Publicado: (2012)

MET in ovarian cancer: Metastasis and resistance?
por: Tang, Chad, et al.
Publicado: (2014)

DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
por: Li, Yang‐ling, et al.
Publicado: (2019)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

Tackling CASMI 2012: Solutions from MetFrag and MetFusion
por: Ruttkies, Christoph, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_jkq1derfu1v765tupro0i74khb